Company & Sponsor Intelligence
National Institute of Mental Health (NIMH)
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed1
Countries1
Therapeutic footprint
parkinsonsunclassified
Indexed studies
NCT00794040A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
adhd · United StatesPHASE2
adhd · United StatesPHASE2
NCT00006177Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study
adhd · United StatesCOMPLETED
adhd · United StatesCOMPLETED
NCT00004451Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients
parkinsons · United StatesNA
parkinsons · United StatesNA
NCT03507218Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
unclassified · United StatesTERMINATED
unclassified · United StatesTERMINATED
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →